Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Chaft
Dr. Jamie Chaft is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Sloan Kettering Monmouth. She received her medical degree from New York University Grossman School of Medicine and has been in practice 11 years. Dr. Chaft accepts several types of health insurance, listed below. She is one of 515 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at Memorial Sloan Kettering Monmouth who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
New York University School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2008 - 2027
NJ State Medical License 2017 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation Start of enrollment: 2008 Apr 01
- Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) Start of enrollment: 2011 Oct 01
- Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant Osimertinib for Resectable-Mutated Non-Small Cell Lung Cancer.Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J Hochmair
Journal of Clinical Oncology. 2025-06-02 - Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.Biagio Ricciuti, Francesca Fusco, Alissa Cooper, Edoardo Garbo, Federica Pecci
JAMA Oncology. 2025-05-22 - 2 citationsHigh-risk features associated with recurrence in stage I lung adenocarcinoma.Cameron N Fick, Elizabeth G Dunne, Stijn Vanstraelen, Nicolas Toumbacaris, Kay See Tan
The Journal of Thoracic and Cardiovascular Surgery. 2025-02-01
Journal Articles
- Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung CancersHelena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
- Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
- Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Crit...J M Isbell, N Rekhtman, J D Wolchok, J E Chaft, Annals of Oncology
- Join now to see all
Press Mentions
Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic ResponsesJune 3rd, 2025- MSK Researchers Present Advances in Lung Cancer Treatment at 2025 ASCO MeetingJune 2nd, 2025
- The Evidence Gap: Immunotherapy Timing in Early-Stage NSCLC?December 23rd, 2024
- Join now to see all
Insurance Accepted
- GHI PPO
United Healthcare - Direct Choice Plus POSUnited Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
